The broader bazaar, as ever, rose 4.15% in the last twenty‑four hours-an upward sip of hope-while WLFI trembled downward by 3.55% to $0.1032. Yet profit‑hunters swirled about, increasing their interest to $156.75 million in transactions, evidence that optimism has not fled the land.
So, Ophir swooped in. A new stake in nCino, according to the SEC filings. It’s always fascinating what other people are doing with their money. Makes you question your own life choices. Like, should I have bought more oat milk? Or perhaps diversified into vintage stamps? Anyway, this purchase represents 3.81% of their U.S. equity assets. Which, in the grand scheme of things, isn’t insignificant. They clearly see something. Or they’re very good at pretending to.
Currently, a slight diminution in value – a mere tremor in the grand scheme – has occurred, mirroring the broader sectoral malaise. The discerning investor, however, is not swayed by such pedestrian fluctuations. Instead, one probes beneath the surface, attempting to discern whether this recent effervescence is a genuine signal, or merely a shimmering mirage conjured by the heat of speculation. To “leg into” this position, as the vulgar parlance has it, or to execute a strategic retreat? That is the question.
Core Scientific has secured a loan of $500 million for 364 days. The loan agreement also includes an option to borrow up to an additional $500 million, if needed.
Let’s start with AST. They’re building satellites that beam cellular signals directly to your phone. Imagine, folks, a world where you can get a signal anywhere. Even in your mother-in-law’s basement! They’re partnering with the big telecom giants – AT&T (T 0.33%) and Verizon (VZ 0.09%) – because apparently, even they haven’t figured out how to get a signal to the middle of nowhere. And get this: they just landed a contract with the U.S. Missile Defense Agency. Yes, you heard that right. They’re building satellites to… well, let’s just say they’re helping us keep an eye on things up there. It’s like a cosmic neighborhood watch program. And they launched their Block 1 BlueBird satellites, which sounds suspiciously like a 1950s jazz band. Then came the Block 2, 3.5 times larger and ten times the data. They’re planning 45-60 in orbit this year, aiming for over 240 eventually. It’s a satellite swarm, folks! A beautiful, data-collecting swarm.
One might expect a chorus of lamentations, but not so. Raymond James, ever the optimist – or perhaps merely the dutiful analyst – persists in offering encouragement. A curious profession, that of bolstering valuations in the face of demonstrable decline.
Bristol Myers Squibb, a purveyor of pharmaceuticals, maintains a vast portfolio, a testament to years of research and, inevitably, the expiration of intellectual property. Last year, ten of its products each generated over a billion dollars in revenue – a considerable sum, yet one shadowed by the looming specter of patent cliffs. The company, like a diligent gardener, cultivates new therapies even as older ones wither, a necessary cycle in this relentless pursuit of profit. The impending loss of exclusivity for Eliquis and Opdivo, its two leading revenue generators, presents a challenge, a tightening of the noose on future earnings. This is not a failure of ingenuity, but a fundamental characteristic of the system – a planned obsolescence inherent in the pursuit of innovation.
One is compelled to ask: is this a moment for acquisition, a calculated risk in the face of diminished returns? Or simply another iteration in the endless cycle of market correction, a process as predictable as it is…unyielding?
The current market capitalization of approximately $349 billion presents a figure that, upon closer inspection, reveals itself to be less a statement of value and more a complex equation with an unknown solution. Valued at roughly 110 times forward earnings and 48 times forward sales, Palantir exists in a state of perpetual anticipation, a constant striving to justify a price that seems to float untethered from earthly concerns. The question, then, is not whether the stock can beat the market, but whether it can indefinitely postpone the moment of its inevitable descent.
The cessation of production for the Model S and Model X is not a defeat, dear reader, but a declaration. Fremont, once a temple to automotive progress, is to become a foundry for automatons. The Optimus, a humanoid robot, is the new muse, and robotaxis, the gilded chariots of a driverless age. It is a bold wager, a testament to the enduring human belief that progress lies not in refinement, but in radical reinvention.